32 results about "Insulinotropin" patented technology

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

The invention relates to the field of microorganisms, and provides an acid-producing propionibacterium BL8 with hypoglycemic and anti-aging functions and application of the acid-producing propionibacterium BL8, the acid-producing propionibacterium BL8 is preserved in China General Microbiological Culture Collection Center on December 20, 2024, and the preservation number is CGMCC No. 33134. The acid-producing propionibacterium BL8 disclosed by the invention can be used for inhibiting the activity of DPP4, promoting insulin secretion of INS-1, and inhibiting the activity of acetylcholin esterase and excellent cellulase activity. The blood sugar can be reduced; the memory is improved, and the Alzheimer disease is prevented and relieved; and the traditional Chinese medicine composition has relatively high research and application values in the aspects of reducing blood sugar and resisting aging.

Incretin analogs and their use. It contains a triple-acting agent protein for human glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor and glucagon (GCG) receptor, and is useful for the treatment of type 2 diabetes (T2D), obesity, non-alcoholic fatty liver disease (NAFLD) and other carbohydrate and lipid metabolism disorders.

Methods and materials for treating mammals having cardiovascular and / or metabolic disease are provided herein. For example, methods and materials for treating mammals having cardiovascular and / or metabolic disease by administering (a) an analog of a natriuretic peptide (NP), such as atrial natriuretic peptide (ANP) or dendroaspis natriuretic peptide (DNP), and (b) a glucagon-like peptide-1 (GLP-1) receptor / glucose-dependent insulinotropic polypeptide (GIP) receptor agonist are provided herein. The NP analogs used in the methods provided herein can be less than 20 amino acids in length and, in some cases, can have one or more variations in their ring portion (as compared to wild type ANP or DNP) that affect the potency of the analog in activating the particulate guanylyl cyclase (GC-A) receptor.

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and / or treating a metabolic disorder and / or muscle atrophy. It also pertains to a method of preventing and / or treating a metabolic disorder and / or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and / or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin or b) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and / or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and / or treating diabetes or prediabetes in a subject.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present invention pertains to a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for use in preventing and / or treating a metabolic disorder and / or muscle atrophy. It also pertains to a method of preventing and / or treating a metabolic disorder and / or muscle atrophy in a subject. It furthermore pertains to use of a) beta-lactoglobulin or b) a nutritional composition comprising beta-lactoglobulin for increasing the level of insulin and / or glucagon in the blood of a subject and the present invention also pertains to a non-therapeutic use or method of a) beta-lactoglobulin orb) a nutritional composition comprising BLG. It also pertains to beta-lactoglobulin (BLG) for use in preventing and / or treating diabetes or prediabetes in a subject. It furthermore pertains to a nutritional composition for use in preventing and / or treating diabetes or prediabetes in a subject.

The application provides a construction method of a cell model for screening hypoglycemic drugs, and belongs to the technical field of biotechnology.The method provided by the application comprises the following steps: cell verification, vector construction and plasmid extraction, cell electroporation, drug screening, stable strain amplification and Q-PCR verification.The application successfully constructs a stable fluorescence reporter model (Min6-ins2>EGFP) based on Min6 cells, and verifies the specificity and sensitivity of the model to insulin secretion promoting drugs through positive drug verification.The model is simple to operate, can be monitored in real time, is suitable for high-throughput screening, can be effectively used for hypoglycemic activity evaluation of complex components such as chemical drugs and traditional Chinese medicines, and provides a reliable tool for early screening of hypoglycemic drugs.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present disclosure relates to a combination therapy comprising GLP-2, and an insulinotropic peptide, a TNFα inhibitor, or both for preventing, improving, or treating bowel disease.

The invention relates to the field of medical biology, in particular to a tri-agonist polypeptide compound which has triple agonist activity on a glucagon-like peptide-1 receptor (GLP-1 R), a glucose-dependent insulinotropic polypeptide receptor (GIP R) and a glucagon receptor (GCG R) and is shown in a general formula (I) or salt or solvate of the tri-agonist polypeptide compound, and relates to application of the tri-agonist polypeptide compound in treatment of metabolic syndromes.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucagon-like peptide-1 (GLP-1) and glucagon (Gcg) co-agonist.

The invention discloses an auricularia auricula polysaccharide-based tablet candy capable of relieving hyperglycemia and a preparation method of the auricularia auricula polysaccharide-based tablet candy, and relates to the technical field of biology, the auricularia auricula polysaccharide-based tablet candy comprises the following raw materials by weight: 20-30 parts of auricularia auricula polysaccharide; 35 to 45 parts of a filling agent; 20 to 30 parts of a disintegrating agent; 3-8 parts of a functional auxiliary material; 0.5 to 1.5 parts of a lubricant; 2-5 parts of an adhesive; wherein the auricularia auricula polysaccharide is extracted by adopting a targeted enzymolysis technology, the weight-average molecular weight is 1.0 * 10 <-2.0 > * 10 < Da >, and the bioavailability is high; the functional auxiliary material comprises an insulin secretion promoting factor and a sugar absorption inhibiting factor, and is specifically a compound of chromium yeast and a mulberry leaf extract according to a mass ratio of (1-3): 1. All the components are prepared into the tablet candy through a specific process, all the active components have a synergistic effect, and the blood sugar reducing effect can be achieved in multiple ways and multiple targets of promoting insulin secretion, inhibiting sugar absorption, improving insulin sensitivity and the like. The product is good in taste, fast in disintegration and convenient to take, can be used for preparing functional food for assisting management of type 2 diabetes, and has the blood sugar reducing effect obviously better than that of a traditional product with extracted polysaccharide or single functional factor.

Provided herein are peptides and peptide conjugates having activity as triple agonists of the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide 1 (GLP-1) receptor, and the glucagon (GCG) receptor. The peptide conjugates provided herein are cross-linked via a half-life extending staple. The peptides and peptide conjugates may be used for blood glucose management and treating conditions such as diabetes mellitus, obesity, dyslipidemia, metabolic syndrome, and metabolic dysfunction-associated steatohepatitis (MASH).

A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.

A zinc-glucagon-like peptide composition for inducing an insulinotropic response in a patient through oral administration is disclosed. The composition includes a glucagon-like peptide (GLP-1) such as a GLP-1 analogue, as a polypeptidic chain of amino acids joined by peptide linkages and ionically bound to zinc. The glucagon-like peptide is first incubated with a chelating agent and thereafter incubated with a zinc salt solution, wherein the zinc is ionically bound to the chelated glucagon-like peptide. The zinc-glucagon-like peptide is then packaged for oral administration and orally administered for intestinal absorption of the glucagon-like peptide.

A series of pharmaceutical compositions containing polypeptide dual agonist compounds and pharmaceutically acceptable salts thereof, wherein same have dual agonist effects on a human glucagon-like peptide-1 (GLP-1) receptor and a human blood glucose-dependent insulinotropic polypeptide (GIP) receptor, and can be used for treating non-insulin-dependent diabetes, insulin-dependent diabetes, obesity and other related diseases.

Described herein are compositions formulated for oral administration comprising luteolin, luteolin-7-0-β-D-glucoside, or mixtures thereof, wherein luteolin, luteolin-7-0-β-D-glucoside, or mixtures thereof activate all of the glucagon-like peptide 1 receptor (GLP-1R), glucose-dependent insulinotropic peptide receptor (GIPR), and glucagon receptor (GCG). Luteolin and luteolin-7-0-β-D-glucoside are triple agonists of GLP-1, GIPR, and GCGR. Further, described herein are methods of treating and / or preventing type 2 diabetes and obesity by administering the described compositions. Further, described herein are methods of activating all GLP-1R, GIPR, and GCGR comprising providing a composition comprising a triple agonist of all GLP-1R, GIPR, and GCGR, wherein the triple agonist is luteolin and / or luteolin-7-0-β-D-glucoside.

A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.

Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.

The present disclosure provides engineered hepatocytes or hepatocyte progenitor cells that secrete an incretin, such as glucagon-like peptide-1 (GLP-1) receptor agonist (RA). The hepatocytes or hepatocyte progenitor cells are engineered with an exogenous polynucleotide that includes a promoter sequence; a secretory signal; and a coding sequence encoding the polypeptide. The coding sequence is operably linked to the promoter sequence and the secretory signal to drive expression and secretion of the incretin.

This invention provides a novel protein. Experimental results have shown that the protein has agonist activity at three receptors, namely the glucagon-like peptide 1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon (Gcg) receptor, and has both blood glucose lowering and body weight reducing functions.

The present application relates to the field of medicine biology, specifically relates to a kind of triple agonist polypeptide compound of general formula (I) or its salt or solvate with triple agonist activity to glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIP R) and glucagon receptor (GCG R), and to its application in treating metabolic syndrome.

The present disclosure relates to peptide compounds which are mono- or dual-agonists of the human glucagon-like peptide- 1 (GLP-1) receptor (GLP1R) and the human glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR). The invention also relates to peptide compounds that are suitable for oral administration. Thes peptide compounds of the invention may be useful in the treatment of type 2 diabetes mellitus (T2DM) and obesity.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The invention relates to a GLP-1-, GIP and GCG receptor tri-agonist and application thereof. According to the present invention, the corresponding compounds have the agonist effect on the human glucagon-like peptide-KGhiagon-likepfoptimal-l (GLP-1) receptor, the human glucose-dependent insulinotropic polypeptide (Glucose-dedentin sublinotropic polypeptide, GIP) receptor, and the human glucagon (Glucagon, GCG) receptor, and can be used for prevention and / or treatment of metabolic disorder related diseases or symptoms.

An incretin analog and a use thereof are provided. The incretin analog contains a triple agonist protein for activating a human glucose-dependent insulinotropic polypeptide (GIP) receptor, a glucagon-like peptide-1 (GLP-1) receptor, and a glucagon (GCG) receptor, and can be used for treating type 2 diabetes (T2D), obesity, non-alcoholic steatohepatitis, and other glycolipid metabolism disorders.

A novel triple agonist having activities for all of glucagon-like peptide-1 (GLP-1) receptor, a glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon receptors is disclosed. Compositions containing the triple agonist and method for the prevention or treatment of obesity employing the triple agonist or the composition are disclosed.

Provided is a bifunctional fusion protein. Specifically provided are a bifunctional fusion protein which specifically binds to a glucose-dependent insulinotropic polypeptide receptor and a glucagon-like peptide-1 receptor and the use thereof.

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.